Cytokinetics CYTK
NASDAQ CYTK
$65.60 -0.02 (-0.03%)
At close: Oct 2, 2026 · 4:00 PM EDT

Cytokinetics (CYTK) Gains from Sales and Divestitures (2013 - 2017)

Updated

Cytokinetics' Gains from Sales and Divestitures was -$15,000 in Q4 2017, compared with $19,000 a year earlier.

Analysis

Cytokinetics (CYTK) Gains from Sales and Divestitures (2013 - 2017) Analysis & Trends

For FY2017, Gains from Sales and Divestitures at Cytokinetics came in at $67,000, up 272.2% from FY2016.

  • Gains from Sales and Divestitures shows a five-year compound annual growth rate of 101.8% (FY2012 to FY2017).
  • In earlier years, Gains from Sales and Divestitures was $18,000 in FY2016 (unchanged), $18,000 in FY2015 and $79,000 in FY2013.
  • The Q4 2017 figure marks the lowest quarterly Gains from Sales and Divestitures in data going back to Q3 2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Cytokinetics 9.12 Bn 5.29 Bn 25.89 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 -15,000.00
Mar 31, 2017 82,000.00
Dec 31, 2016 19,000.00
Sep 30, 2016 -3,000.00
Jun 30, 2016 2,000.00
Dec 31, 2015 18,000.00
Dec 31, 2013 77,000.00
Sep 30, 2013 -1,000.00
API Access

Cytokinetics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CYTK&period=max&api_key=YOUR_API_KEY